(SGMO) Sangamo Therapeutics - Performance 43.3% in 12m
Compare SGMO with Indices, Sectors and Commodities and Bonds. Who performs better in which timeframe?
Performance Rating
-65.55%
#95 in Group
Rel. Strength
86.10%
#1107 in Universe
Total Return 12m
43.27%
#30 in Group
Total Return 5y
-92.06%
#119 in Group
P/E -
(?) Percentile in Group
P/E Forward -
(?) Percentile in Group
PEG -
(?) Percentile in Group
FCF Yield -41.57%
(?) Percentile in Group
12m Total Return: SGMO (43.3%) vs XBI (-12.3%)

5y Drawdown (Underwater) Chart

Top Performers in Biotechnology
Overall best picks of Peer Group Selected by proven GARP Predictive Metrics, sorted by Growth Rating
Symbol | 1m | 12m | 5y | P/E | P/E Forward | PEG | EPS Stability |
EPS CAGR |
---|---|---|---|---|---|---|---|---|
UTHR NASDAQ United Therapeutics |
10.1% | 18% | 166% | 12.1 | 11 | 1.43 | 74.6% | 16.1% |
HLN NYSE Haleon |
14.3% | 31.2% | 47% | 24.4 | 20.2 | 1.79 | 69.1% | 13.6% |
AMGN NASDAQ Amgen |
-2.93% | -8.78% | 30.7% | 25.5 | 13.5 | 0.95 | 0.60% | 41% |
LONN SW Lonza |
9.55% | 9.34% | 30.4% | 67.1 | 35.1 | 1.28 | 2.20% | -12.5% |
BIM PA Biomerieux |
0.78% | 17.8% | -2.14% | 32.5 | 25.2 | 1.52 | -38.5% | -25.1% |
KMDA NASDAQ Kamada |
21.4% | 25.3% | -4.13% | 26.6 | 23.9 | 0.96 | 32.5% | 3.93% |
NBIX NASDAQ Neurocrine Biosciences |
34.3% | -15.5% | 3.48% | 32.3 | 21.6 | 0.27 | 68.0% | 31.9% |
ERF PA Eurofins Scientific SE |
20.4% | -0.39% | 7.63% | 26.6 | 13.6 | 0.56 | -66.6% | -17.1% |
Performance Comparison: SGMO vs XBI vs S&P 500
XBI (SPDR S&P Biotech ETF) is the Sector Benchmark for SGMO
Total Return (including Dividends) | SGMO | XBI | S&P 500 |
---|---|---|---|
1 Month | 14.65% | 11.81% | 13.81% |
3 Months | -37.95% | -13.61% | -6.30% |
12 Months | 43.27% | -12.29% | 10.65% |
5 Years | -92.06% | -24.89% | 107.77% |
Trend Score (consistency of price movement) | SGMO | XBI | S&P 500 |
1 Month | -7.00% | 72.9% | 83% |
3 Months | -85.2% | -83% | -75.3% |
12 Months | 43.4% | -51.6% | 50.1% |
5 Years | -90.0% | -53.9% | 84.1% |
Relative Strength (compared with Indexes) | Rank in Peer Group | vs. XBI | vs. S&P 500 |
1 Month | #76 | 2.55% | 0.74% |
3 Month | #164 | -28.2% | -33.8% |
12 Month | #30 | 63.4% | 29.5% |
5 Years | #123 | -89.4% | -96.2% |
FAQs
Does SGMO Sangamo Therapeutics outperforms the market?
Yes,
over the last 12 months SGMO made 43.27%, while its related Sector, the SPDR S&P Biotech (XBI) made -12.29%.
Over the last 3 months SGMO made -37.95%, while XBI made -13.61%.
Over the last 3 months SGMO made -37.95%, while XBI made -13.61%.
Performance Comparison SGMO vs Indeces and Sectors
SGMO vs. Indices SGMO is Over or Underperforming
Symbol | 1w | 1m | 6m | 12m | |
---|---|---|---|---|---|
US S&P 500 | SPY | -4.07% | 0.84% | -70.0% | 32.6% |
US NASDAQ 100 | QQQ | -4.26% | -2.71% | -70.2% | 31.6% |
US Dow Jones Industrial 30 | DIA | -4.48% | 4.66% | -69.7% | 35.6% |
German DAX 40 | DAX | -4.05% | -0.31% | -96.3% | 17.6% |
Shanghai Shenzhen CSI 300 | CSI 300 | -6.25% | 2.82% | -70.8% | 35.9% |
Hongkong Hang Seng | HSI | -7.24% | -5.28% | -78.3% | 29.6% |
India NIFTY 50 | INDA | 0.85% | 9.81% | -70.4% | 43.5% |
Brasil Bovespa | EWZ | -5.12% | -2.59% | -78.7% | 51.6% |
SGMO vs. Sectors SGMO is Over or Underperforming
Symbol | 1w | 1m | 6m | 12m | |
---|---|---|---|---|---|
Communication Services | XLC | -4.71% | 1.24% | -77.0% | 21.7% |
Consumer Discretionary | XLY | -4.45% | 0.42% | -69.0% | 29.0% |
Consumer Staples | XLP | -3.21% | 8.06% | -76.9% | 34.2% |
Energy | XLE | -3.89% | 7.89% | -63.4% | 52.7% |
Financial | XLF | -5.17% | 1.13% | -77.1% | 20.8% |
Health Care | XLV | -1.06% | 13.8% | -65.0% | 47.3% |
Industrial | XLI | -5.76% | -2.17% | -71.4% | 32.3% |
Materials | XLB | -3.87% | 1.09% | -65.1% | 48.5% |
Real Estate | XLRE | -2.75% | 3.11% | -70.7% | 27.8% |
Technology | XLK | -5.15% | -6.57% | -67.1% | 36.2% |
Utilities | XLU | -4.12% | 5.06% | -77.6% | 25.8% |
Aerospace & Defense | XAR | -6.05% | -6.51% | -81.5% | 15.9% |
Biotech | XBI | 2.52% | 2.84% | -49.8% | 55.6% |
Homebuilder | XHB | -4.54% | 3.17% | -56.8% | 50.8% |
Retail | XRT | -5.97% | - | -65.7% | 44.8% |